Loading…
Evogene Ltd. is projected to decline to $0.5207 by 2027, a -3% move from its current price of $0.536. EVGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5088 | $0.5355 | $0.5636 | -0.09% |
| Aug 6 | $0.4977 | $0.535 | $0.5751 | -0.19% |
| Aug 7 | $0.4892 | $0.5345 | $0.584 | -0.28% |
| Aug 8 | $0.4821 | $0.534 | $0.5915 | -0.38% |
| Aug 9 | $0.4759 | $0.5335 | $0.5981 | -0.47% |
| Aug 10 | $0.4703 | $0.533 | $0.6041 | -0.56% |
| Aug 11 | $0.4651 | $0.5325 | $0.6096 | -0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4651 | $0.5325 | $0.6096 | -0.66% |
| Week 2 | $0.4369 | $0.529 | $0.6405 | -1.31% |
| Week 3 | $0.4158 | $0.5255 | $0.6642 | -1.96% |
| Week 4 | $0.3984 | $0.5221 | $0.6842 | -2.60% |
| Week 5 | $0.3833 | $0.5186 | $0.7018 | -3.24% |
| Week 6 | $0.37 | $0.5152 | $0.7176 | -3.87% |
| Week 7 | $0.3579 | $0.5119 | $0.732 | -4.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evogene Ltd. is a computational biology company that operates through subsidiaries in Israel, the United States, Europe and Africa. It runs three segments—Agriculture, Human Health and Industrial Applications—and engages in agricultural activities such as seed traits and ag-chemicals, while also designing novel small molecules for drug development using ChemPass AI, a computational generative AI engine.
The company also focuses on the development and commercialization of castor bean seeds for industrial uses and medical cannabis products. Evogene was incorporated in 1999 and is headquartered in Rehovot, Israel.
Its activities span multiple regions and applications, including collaborations and development programs across its three business lines. These efforts reflect a diversified portfolio within the broader healthcare and agricultural sectors. The description highlights a balance between agricultural trait development, drug design, and specialty industrial crops, anchored by its Israel-based origins and global reach.
Evogene Ltd. trades with a current price of $0.4945 and a market capitalization of $5.99M, with a rank of 4999. The near-term outlook shows a mixed to flat path, with average prices in the forecast around the current level but with a decline projected through 2029 before a potential recovery.
In the multi-year view, the forecast moves from bear-ish to neutral in the early 2030s, then shifts to bullish later in the decade and into the 2040s. The average price for 2040 is $0.7884 and for 2050 is $0.8488, with corresponding ROIs of 59.4% and 71.7%, respectively. By 2032–2035 the outlook returns to neutral territory before turning more positive in 2040 and 2050.
Current metrics and the year-by-year forecast indicate a wide range of outcomes, underscoring the uncertainty and the potential for upside in the long run while highlighting near-term downside risk in a few intermediate years.
A major floor 52.1% below — a decisive break under it would weaken the trend.
The nearest floor, 27.2% below — buyers have tended to step in here.
The nearest ceiling, 17.5% above — a clean break opens room to run.
A major ceiling 64.2% above — clearing it would confirm fresh momentum.
Key EVGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.49 | Buy | $0.4908 | Buy |
| MA 10 | $0.515 | Buy | $0.504 | Buy |
| MA 20 | $0.508 | Buy | $0.5106 | Buy |
| MA 50 | $0.547 | Sell | $0.5595 | Sell |
| MA 100 | $0.6714 | Sell | $0.6615 | Sell |
| MA 200 | $0.8746 | Sell | $0.8694 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.08 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -57.58 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -18.97 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 27.87 | Buy |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 0.47 | Buy |
| ADX (14) | 18.90 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture shows a neutral momentum with RSI14 at 50. The 50-day simple moving average (SMA) is $0.571 and the 200-day SMA is $0.8957, framing a price path around the current level.
Key support sits at $0.39 and resistance at $0.63, with the 30-day price range spanning $0.3373 to $0.7249. These levels outline a trading range that encompasses the current price and provides a reference for near-term price activity.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.39 | $0.536 | $0.6483 | 0% | Neutral | |
| $0.3826 | $0.5207 | $0.765 | -3% | Neutral | |
| $0.3219 | $0.4645 | $0.7266 | -13% | Neutral | |
| $0.254 | $0.3851 | $0.632 | -28% | Bearish | |
| $0.2669 | $0.4231 | $0.7223 | -21% | Bearish | |
| $0.2994 | $0.4949 | $0.874 | -8% | Neutral | |
| $0.3463 | $0.5956 | $1.08 | +11% | Neutral | |
| $0.3412 | $0.6095 | $1.14 | +14% | Neutral | |
| $0.3205 | $0.594 | $1.14 | +11% | Neutral | |
| $0.3094 | $0.5944 | $1.16 | +11% | Neutral | |
| $0.3916 | $0.8702 | $1.87 | +62% | Bullish | |
| $0.437 | $0.9711 | $2.23 | +81% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.39 | $0.536 | $0.6301 | +0.00% |
| September 2026 | $0.3959 | $0.4801 | $0.6066 | -10.43% |
| October 2026 | $0.4004 | $0.492 | $0.6338 | +2.47% |
| November 2026 | $0.4075 | $0.5062 | $0.6623 | +2.89% |
| December 2026 | $0.3895 | $0.4886 | $0.6483 | -3.46% |
Click any year to see its month-by-month EVGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EVGN to range from $0.39 to $0.6483 through 2026. The $0.536 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EVGN price prediction for 2027 points to an average of $0.5207 (low $0.3826, high $0.765) — a potential decline of -3% on today's $0.536. Price action looks broadly range-bound.
In 2028, EVGN is projected to trade between $0.3219 and $0.7266, averaging $0.4645 — a potential decline of -13% from today's $0.536. That is -11% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Evogene Ltd.'s 2029 outlook centres on $0.3851, within a $0.254 to $0.632 range. That is -17% versus the projected 2028 average. That marks a -28% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, EVGN could reach as high as $0.7223, with a base case around $0.4231 and support toward $0.2669 — roughly -21% from $0.536. Expect choppier, lower action through this leg of the cycle.
Expect EVGN to range from $0.2994 to $0.874 through 2031. The $0.4949 average target implies a -8% move from current prices. That is up +17% on the projected 2030 average. Price action looks broadly range-bound.
The EVGN price prediction for 2032 points to an average of $0.5956 (low $0.3463, high $1.08) — a potential gain of +11% on today's $0.536. A consolidation phase looks the most probable path here.
In 2033, EVGN is projected to trade between $0.3412 and $1.14, averaging $0.6095 — a potential gain of +14% from today's $0.536. That is up +2% on the projected 2032 average. Price action looks broadly range-bound.
Evogene Ltd.'s 2034 outlook centres on $0.594, within a $0.3205 to $1.14 range. That is -3% versus the projected 2033 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, EVGN could reach as high as $1.16, with a base case around $0.5944 and support toward $0.3094 — roughly +11% from $0.536. Price action looks broadly range-bound.
Expect EVGN to range from $0.3916 to $1.87 through 2040. The $0.8702 average target implies a +62% move from current prices. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EVGN price prediction for 2050 points to an average of $0.9711 (low $0.437, high $2.23) — a potential gain of +81% on today's $0.536. Momentum favours further upside here.
Investing $1,000 in EVGN today (≈ 1,865.671642 EVGN) could be worth
$1,811.71
+$811.71 (+81%) by 2050 · US Dollar
Based on the average projected EVGN price of $0.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVGNwould be worth at today's price.
$1,000 invested in EVGN on Jul 31, 2025 (≈ 833.3333 EVGN) would be worth
$446.67
-$553.33 (-55.3%) today · 0.45× · US Dollar
Based on a EVGN entry price of $1.2 vs. today's $0.536.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.54 | $992.59 | -0.7% |
| 1 month ago | $0.44 | $1,218.18 | +21.8% |
| 3 months ago | $0.77 | $696.1 | -30.4% |
| 6 months ago | $1.02 | $525.49 | -47.5% |
| 1 year ago | $1.2 | $446.67 | -55.3% |
| All time (5.0y) ago | $27.6 | $19.42 | -98.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVGN forecast.
$1.10 is within our bullish range by 2033, but above the base case.
Implied market cap at $1.10: $13.31M
The multi-year forecast shows a challenging start through 2029, with 2026-2027 labeled as NEUTRAL and 2028-2029 labeled as BEARISH. The 2030 forecast carries a negative return of -22.1% with an average price of $0.3853 and a range from $0.2387 to $0.6676.
From 2031 through 2035, the outlook improves to NEUTRAL with gradual price increases: 2031 avg $0.4517, 2032 avg $0.54, 2033 avg $0.5649, 2034 avg $0.5377, and 2035 avg $0.5289. The ROIs for these years are -8.7%, 9.2%, 14.2%, 8.7%, and 7%, respectively.
The forecast turns bullish in 2040, with an average of $0.7884 and a max of $1.73, yielding a 59.4% ROI. This bullish stance continues into 2050, which shows an average of $0.8488, a max of $1.95, and a 71.7% ROI. These long-run projections illustrate a path from near-term uncertainty to meaningful upside potential, while acknowledging that these are estimates, not guarantees.
Tap a question to reveal the answer.
The forecast shows min $0.2387, avg $0.3853, max $0.6676 with an ROI of -22.1% and sentiment BEARISH.
The year-by-year outlook is mixed: 2026 NEUTRAL, 2027 NEUTRAL, 2028 BEARISH, 2029 BEARISH, 2030 BEARISH, then 2031–2035 NEUTRAL before 2040 and 2050 turn BULLISH.
Yes, the forecast shows higher-price points: max $1.07 in 2033, $1.73 in 2040, and $1.95 in 2050.
RSI14 is 50, with SMA50 at $0.571 and SMA200 at $0.8957. The stock has support at $0.39 and resistance at $0.63, and the 30-day range is $0.3373 to $0.7249.
Current price is $0.4945 with a market cap of $5.99M and a rank of 4999.
Evogene Ltd. Community Discussion
0Share your Evogene Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.